Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 12/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 12/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 11/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7225665 | 0.81 | GABRA1 (0.58) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7234152 | 0.74 | GABRA1 (0.60) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7231276 | 0.73 | GABRA1 (0.66) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7224559 | 0.71 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7227602 | 0.71 | GABRG2 (0.64) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL13416088 | 0.71 | CA1 (0.45) | — | |
| SCHEMBL5261766 | 0.70 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7232228 | 0.70 | GABRG2 (0.61) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7224413 | 0.70 | GABRA1 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL15086987 | 0.69 | PPARG (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642229-B2 | Treatment of adverse neurological conditions | MERCK SHARP & DOHME LTD. | 2003-11-04 | — | — | US | disclosed |